Navigation Links
Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Date:6/4/2009

SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced a strategic restructuring to focus its operations on the development of ANA598, in particular a proposed Phase II study in hepatitis C patients of ANA598 in combination with pegylated interferon-alpha and ribavirin.

As part of this restructuring, the Company intends to suspend further development of ANA773 and is reducing its workforce by approximately 40%. Pending the outcome and analysis of data from current cohorts in ongoing studies in hepatitis C and oncology, Anadys intends to manage the ANA773 programs as potential out-licensing opportunities.

"We have now completed three Phase I studies of ANA598 and we have seen potent antiviral activity, as well as good tolerability," said Steve Worland, Ph.D., President and CEO of Anadys. "As we complete preparations for the first Phase II study of ANA598 in combination with interferon and ribavirin, we have decided to focus our future investments on this important asset and to take these cost-sparing measures which we expect to ensure our ability to complete the Phase II study with our expected cash resources. The proposed Phase II study is expected to provide important data at the end of this year and in the first two quarters of 2010."

The Company anticipates the reduction in force to generate annual cash expense savings of between approximately $4.0 million and $5.0 million. The Company estimates that it will incur one-time cash charges of approximately $1.1 million in severance costs and $0.2 million in continuation of benefits and outplacement services. The Company will retain the clinical development infrastructure required to conduct the Phase II study of ANA598, key capabilities directed toward pharmaceutical development and next-generation non-n
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015  Endo International plc (NASDAQ: ... De Silva , President and CEO, will present a corporate ... New York City on Wednesday, May 20, 2015 ... and audio archive for the event will be available on ... Relations, and then the link to the event. Participants should ...
(Date:5/6/2015)... 6, 2015  Oxis Biotech, Inc. (OXIS), a wholly ... announced today that Cassian Yee , M.D., Professor, ... at the University of Texas MD Anderson Cancer Center ... Professor, Department of Immunology, Division of Cancer Medicine, and ... Research at the University of Texas MD Anderson Cancer ...
(Date:5/6/2015)... The Remedy Group , the premier ... specialty pharmacy industry, will be exhibiting, presenting, and is ... Summit. The Summit will be held May 4-8, 2015 ... the largest annual gathering for the specialty pharmacy industry. ... providers, pharma/biotech manufacturers, and payers, to learn more about ...
(Date:5/5/2015)...  23andMe, Inc., the leading personal genetics company, today ... in collaboration with Pfizer Inc. The companies aim ... commonly known as lupus, into the study to help ... also in collaboration with the Lupus Research Institute, and ... Approximately 1.5 million people in the U.S. suffer ...
Breaking Biology Technology:Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 2Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 3The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3
... Application Breadth of Market-Leading ... IVIS Instrument Family - ... HOPKINTON, Mass., Sept. 9 Caliper Life,Sciences, Inc. (Nasdaq: CALP ... sciences research, today introduced the IVIS(R),Kinetic preclinical in vivo imaging system. The ...
... InNexus,Biotechnology Inc., (TSX: IXS.V, OTC Bulletin Board: IXSBF, ... next,generation of monoclonal antibodies based on its Dynamic ... Board of Directors., Mr. Warden was a ... his 23 years of practice, he has represented ...
... workers exposed to flammable vapors or dusts be protected by UL ... now has a significant offering of these lights available for oil ... ... Dallas, TX (PRWEB) September 9, 2008 -- OSHA requirements mandate that ...
Cached Biology Technology:Caliper Launches Small Animal Molecular Imaging System Enabling Real-Time Video Observation 2Caliper Launches Small Animal Molecular Imaging System Enabling Real-Time Video Observation 3InNexus Biotechnology Strengthens Patent Team With New Leadership 2Explosion Proof Fluorescent Lights Keep Paint Spray Booths and Oil Rig Workers Safe 2
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/6/2015)... 6, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND ... NXT-ID introduces a new revolutionary method and ... the use of miniature antenna modules for multiple ...
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... in French . New research reveals ... investors trading stocks are faced with the same fundamental challenge ... and benefits. A neuroeconomics study from the Montreal Neurological Institute ... brain employs two separate regions and two distinct processes in ...
... have developed a new concept for rechargeable batteries. Based ... anions between the electrodes -- it promises to enhance ... factors. Operational safety is also increased, as it can ... for the first time in the Journal of ...
... the October 20th edition of the journal Cell Host ... of the Departments of Medicine and Microbiology at NYU Langone ... University, present a model for understanding how cancer evolves in ... our body, the microbiome. The authors suggest that ...
Cached Biology News:What you want vs. how you get it 2What you want vs. how you get it 3What you want vs. how you get it 4Fluoride shuttle increases storage capacity 2
...
... PP2A1, purified Formulation: 50mM Tris-HCl, ... Brij-35, 0.2mM PMSF, 1mM benzamidine, ... Properites: PP2A1 (Protein Phosphatase 2A1) ... ammonium sulfate precipitation, QSepharose,amino-hexyl agarose, ...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
...
Biology Products: